Nasdaq questioned the identities and backgrounds of Chinese IPO investors; China rolls out new phase of Golden Tax System; and U.S. Congress attempts to prevent Chinese companies from using de minimis loophole to avoid tariffs
SAMR prohibits monopoly agreements that fix or modify pharmaceutical prices. Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC. Guidelines are provided for the methods of monitoring data interface security risks.
U.S. plans to restrict Chinese software in electric and internet-connected cars; China increases control over offshore capital flows; and Chinese firms plan to expand into the U.S. Midwest but have regulatory concerns.
Revised Chinese Company Law requires mandatory worker representation in boardrooms; Shanghai's biomedical measures catch the most attention; and Merchants of Pinduoduo's international arm, Temu, struggle to sue the company due to its complex structure.
The amended PRC Company Law will have many, far-reaching effects, including motivating companies to reduce their registered capital in order to optimize capital utilization. Daisy Duan, Yingjie Yang and Cuishi Li of King & Wood Mallesons introduce the motivations and tax implications associated with one possible route: formal capital reductions
WeRide IPO shows another green light for overseas listing of Chinese companies; China imposes new regulations for local authorities to better implement its state secrets law overhaul; and two Chinese state departments release new rules for QFII to stimulate foreign securities investment.